S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS
<p>Abstract</p> <p>Background</p> <p>This study reports on clinical data from an 8-week open-label study of 20 HIV-seropositive individuals, diagnosed with Major Depressive Disorder (DSM-IV), who were treated with SAM-e (S-Adenosylmethionine). SAM-e may be a treatment a...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2004-11-01
|
| Series: | BMC Psychiatry |
| Online Access: | http://www.biomedcentral.com/1471-244X/4/38 |
| _version_ | 1811293418107699200 |
|---|---|
| author | Shippy R Andrew Mendez Douglas Jones Kristina Cergnul Irene Karpiak Stephen E |
| author_facet | Shippy R Andrew Mendez Douglas Jones Kristina Cergnul Irene Karpiak Stephen E |
| author_sort | Shippy R Andrew |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>This study reports on clinical data from an 8-week open-label study of 20 HIV-seropositive individuals, diagnosed with Major Depressive Disorder (DSM-IV), who were treated with SAM-e (S-Adenosylmethionine). SAM-e may be a treatment alternative for the management of depression in a population reluctant to add another "pill" or another set of related side effects to an already complex highly active antiretroviral therapy (HAART) regimen.</p> <p>Methods</p> <p>The Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression Inventory (BDI) were used to assess depressive symptomatology from 1,2,4,6 and 8 weeks after initiation of treatment with SAM-e.</p> <p>Results</p> <p>Data show a significant acute reduction in depressive symptomatology, as measured by both the HAM-D and the BDI instruments.</p> <p>Conclusions</p> <p>SAM-e has a rapid effect evident as soon as week 1 (<it>p </it>< .001), with progressive decreases in depression symptom rating scores throughout the 8 week study.</p> |
| first_indexed | 2024-04-13T05:01:07Z |
| format | Article |
| id | doaj.art-ce20b033f8dd488e93db1ceca5481a81 |
| institution | Directory Open Access Journal |
| issn | 1471-244X |
| language | English |
| last_indexed | 2024-04-13T05:01:07Z |
| publishDate | 2004-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Psychiatry |
| spelling | doaj.art-ce20b033f8dd488e93db1ceca5481a812022-12-22T03:01:19ZengBMCBMC Psychiatry1471-244X2004-11-01413810.1186/1471-244X-4-38S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDSShippy R AndrewMendez DouglasJones KristinaCergnul IreneKarpiak Stephen E<p>Abstract</p> <p>Background</p> <p>This study reports on clinical data from an 8-week open-label study of 20 HIV-seropositive individuals, diagnosed with Major Depressive Disorder (DSM-IV), who were treated with SAM-e (S-Adenosylmethionine). SAM-e may be a treatment alternative for the management of depression in a population reluctant to add another "pill" or another set of related side effects to an already complex highly active antiretroviral therapy (HAART) regimen.</p> <p>Methods</p> <p>The Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression Inventory (BDI) were used to assess depressive symptomatology from 1,2,4,6 and 8 weeks after initiation of treatment with SAM-e.</p> <p>Results</p> <p>Data show a significant acute reduction in depressive symptomatology, as measured by both the HAM-D and the BDI instruments.</p> <p>Conclusions</p> <p>SAM-e has a rapid effect evident as soon as week 1 (<it>p </it>< .001), with progressive decreases in depression symptom rating scores throughout the 8 week study.</p>http://www.biomedcentral.com/1471-244X/4/38 |
| spellingShingle | Shippy R Andrew Mendez Douglas Jones Kristina Cergnul Irene Karpiak Stephen E S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS BMC Psychiatry |
| title | S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS |
| title_full | S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS |
| title_fullStr | S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS |
| title_full_unstemmed | S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS |
| title_short | S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS |
| title_sort | s adenosylmethionine sam e for the treatment of depression in people living with hiv aids |
| url | http://www.biomedcentral.com/1471-244X/4/38 |
| work_keys_str_mv | AT shippyrandrew sadenosylmethioninesameforthetreatmentofdepressioninpeoplelivingwithhivaids AT mendezdouglas sadenosylmethioninesameforthetreatmentofdepressioninpeoplelivingwithhivaids AT joneskristina sadenosylmethioninesameforthetreatmentofdepressioninpeoplelivingwithhivaids AT cergnulirene sadenosylmethioninesameforthetreatmentofdepressioninpeoplelivingwithhivaids AT karpiakstephene sadenosylmethioninesameforthetreatmentofdepressioninpeoplelivingwithhivaids |